We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.675 | 4.36 | 4.99 | - | 60,335 | 08:00:27 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.53 | 9.41M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 30/9/2020 00:47 | Found this..https://twitte | bobaxe1 | |
| 29/9/2020 20:49 | BROKERS name aim top picks - | postme | |
| 29/9/2020 20:20 | Good posts ... but it looks like SNG are weeks away .. maybe months The share price will suffer.. I'm certain of that unfortunately | amaretto1 | |
| 29/9/2020 18:51 | Cont’d from above ——— ‘Is it the intention to extend the MAP to outside of Europe? Yes, every country has their own schemes. Some countries are easier to work with than others (according to Clinigen). If Clinigen want to talk to other KOLs in other countries then that is fine by us If the MAP is extended to the USA, would you intend to do any direct to consumer advertising there? We would be surprised if you were allowed to do that without a full approval Have you completed all the scale up and validation work required for producing 100,000 treatments per month? This work started back in April, we see it as low risk, so we are getting on with it and creating the reports, it is not completed, it all comes together at the end If so, will the product from these batches be used for the initial MAP supplies? Some of this material will be used for post approval supplies, MAP supplies will probably come from smaller scale batches. We will use what we can, we won’t be giving it away for free What sort of regulatory approval will be required to commence the MAP in Europe, will it be done on a country by country basis in Europe, or will it be a centralised procedure? Clinigen will manage the formal process when patients meet certain criteria. Will you do any Interviews on the MAP announcement? We won’t do any interviews on the MAPs or the interims. The next interviews are likely to be on feedback on Regulatory interactions, scale ups and possibly peer review publication, or whatever comes first. ——— | wetdream | |
| 29/9/2020 18:24 | Ha, is that English or just random key pressing LOL | guss |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
